Please assess the completion status of the following clinical trial:

Trial Title: Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent to the study~* age \>= 55 years at randomization. There is no upper age limit~* systolic blood pressure \>= 150 mmHg in 2 visits at distance of 7-14 days, irrespective of diastolic pressure. Duration of treatment before visit 1 must be at least 12 weeks~* at least one additional risk factor including the following:~* current cigarette smoking~* total cholesterol \>= 20 mmg/dl, or High Density Lipoproteins (HDL) \< 40 mg/dl, or Low Density Lipoproteins (LDL) cholesterol \>= 130 mg/dl~* family history of cardiovascular disease in male first degree relative \< 55 years or female first degree relative \< 65 years~* previous TIA or stroke~* previous coronary artery disease~* history of peripheral occlusive arterial disease (claudication intermittens associated with angiographic or echographic evidence of \> 60% stenosis)~Exclusion Criteria:~* diabetes (fasting glucose \> 125 mg/dl in two samples or ongoing diabetic treatment)~* renal failure, defined by a serum creatinine \> 2.0 mg/dl~* chronic atrial fibrillation or flutter~* clinically significant hepatic or hematological disorders, alcoholism, drug addiction~* causes precluding ECG interpretation for LVH: complete right or left bundle block, Wolff-Parkinson-White syndrome, previous Q-wave myocardial infarction~* any disease causing reduced life expectancy~* unwilling to participate~* significant (more than traces of) valvular heart disease

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intensive Strategy (Type: OTHER): None
- Usual Strategy (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).